Inositol pyrophosphates, and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/663
A61K-031/662
C07F-009/02
C07F-009/00
출원번호
UP-0328313
(2006-01-09)
등록번호
US-7618954
(2009-11-27)
발명자
/ 주소
Nicolau, Yves Claude
Lehn, Jean Marie
Fylaktakidou, Konstantina
Greferath, Ruth
출원인 / 주소
NormOxys, Inc.
Universite de Strasbourg
대리인 / 주소
King & Spalding LLP
인용정보
피인용 횟수 :
15인용 특허 :
67
초록▼
The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions th
The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.
대표청구항▼
We claim: 1. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation
We claim: 1. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive. 2. The method of claim 1, wherein the composition is administered orally. 3. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal red blood cells previously treated with a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, a an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive. 4. A method of treating a mammal afflicted with a cardiovascular disease, comprising the step of administering to said mammal a therapeutically effective amount of a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive. 5. The method of claim 4, wherein the composition is administered orally. 6. A method of treating a mammal afflicted with a cardiovascular disease comprising the step of administering to said mammal red blood cells previously treated with a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive. 7. A method of improving the oxygen delivering capability of mammalian blood, comprising the step of adding to a volume of mammalian blood a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive. 8. A method of incorporating a therapeutically useful substance into mammalian red blood cells, comprising the step of treating a sample of mammalian red blood cells with a compound represented by structure I: wherein: C+ represents independently for each occurrence an aliphatic ammonium cation, an alkali metal cation, an alkaline earth cation, or other suitable metal cation; and A represents an anionic ligand for a mammalian cellular receptor, wherein said anionic ligand comprises 1, 2, or 3 internal pyrophosphate rings; and n is an integer in the range of 1 to 10 inclusive, wherein said compositions or compound comprises said therapeutically useful substance. 9. The method of claim 1, wherein A is represented by the compound of structure II. 10. The method of claim 9, wherein C is sodium and n is 6. 11. The method of claim 1, wherein the mammal is afflicted with a cardiovascular disease. 12. The method of claim 11, wherein the cardiovascular disease is a coronary infarction, a pulmonary disease, congestive heart failure, a myocardial infarction, a peripheral vascular disease, stroke, an intermittent claudication, or arteriosclerosis. 13. The method of claim 12, wherein the cardiovascular disease is congestive heart failure. 14. The method of claim 4, wherein A is represented by the compound of structure II: 15. The method of claim 14, wherein C is sodium and n is 6. 16. The method of claim 4, wherein the cardiovascular disease is a coronary infarction, a pulmonary disease, congestive heart failure, a myocardial infarction, a peripheral vascular disease, stroke, an intermittent claudication, or arteriosclerosis. 17. The method of claim 16, wherein the cardiovascular disease is congestive heart failure. 18. The method of claim 6, wherein the cardiovascular disease is a coronary infarction, a pulmonary disease, congestive heart failure, a myocardial infarction, a peripheral vascular disease, stroke, an intermittent claudication, or arteriosclerosis. 19. The method of claim 18, wherein the cardiovascular disease is congestive heart failure.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (67)
Siren Matti (Montagnola/Lugano CHX), A method of achieving an immunosuppressive effect.
Ropars Claude (Tours FRX) Nicolau Yves (La Chapelle St Mesmin FRX) Chassaigne Maurice (St Cyr S. Loire FRX), Apparatus for encapsulating biological active substances into erythrocytes.
Abraham Donald J. (Murrysville PA) Woltersdorf ; Jr. Otto W. (Chalfont PA) Cragoe ; Jr. Edward J. (Lansdale PA), Compounds useful in treating sickle cell anemia.
Abraham Donald J. (Murrysville PA) Woltersdorf ; Jr. Otto W. (Chalfont PA) Cragoe ; Jr. Edward J. (Lansdale PA), Compounds useful in treating sickle cell anemia.
Abraham Donald J. (Murrysville PA) Woltersdorf ; Jr. Otto W. (Chalfont PA) Cragoe ; Jr. Edward J. (Lansdale PA), Compounds useful in treating sickle cell anemia.
Nicolau Yves-Claude (Mulheim-Ruhr DEX) Gersonde Klaus (Aachen DEX), Controlled improvement of the O2release by intact erythrocytes with lipid vesicles.
Ropars Claude (Tours FRX) Nicolau Yves C. (La Chapelle St Mesmin FRX) Chassaigne Maurice (St Cyr S. Loire FRX), Encapsulating biological active substances into erythrocytes.
Roth Duane J. (La Jolla CA) Keipert Peter E. (San Diego CA) Faithfull Nicholas S. (The Woodlands OH GB2) Zuck Thomas F. (Cincinnati OH) Riess Jean G. (Nice FRX), Facilitated oxygen delivery in conjunction with hemodilution.
Kilbourn Robert G. (Houston TX) De Angelo Joseph (Hamtramck MI) Bonaventura Joseph (Beaufort NC), Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein.
Goodrich ; Jr. Raymond P. (Pasadena CA) Williams Christine M. (Pasadena CA) Franco Robert S. (Cincinnati OH) Weiner Murray (Cincinnati OH), Lyophilization of red blood cells.
Nicolau Yves C. (Chestnut Hill MA) Bruggemann Ulrich (Cambridge MA) Mouneimne Youssef (College Station TX) Roux Eric C. (Framingham MA), Method and apparatus for encapsulation of biologically-active substances in cells.
Franco Robert S. (1825 Sandcliff Dr. Cincinnati OH 45230) Weiner Murray (8915 Spooky Ridge La. Cincinnati OH 45242), Method for altering red blood cell function and survival.
Franco Robert S. (1825 Sandcliff Dr. Cincinnati OH 45230) Weiner Murray (8915 Spooky Ridge La. Cincinnati OH 45242), Method for introducing desired agents into red blood cells.
Teicher Beverly A. (Needham MA) Rausch Carl W. (Medford MA) Hopkins ; 2nd Robert E. (Scituate MA), Method for treating a tumor with ionizing radiation.
Siren Matti (Lugano CHX) Blake David (Worchestershire GBX), Method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug.
Abraham Donald J. (Murrysville PA) Cragoe ; Jr. Edward J. (Lansdale PA) Woltersdorf ; Jr. Otto W. (Chalfont PA), Method of treating a person for sickle cell anemia.
Siren Matti (Montagnola/Lugano CHX) Lofkvist Bertil (Perstorp SEX) Edvinsson Lars (Lund SEX), Method of treating renal disorders with inositoltriphosphate.
Sabin Robert (Goosedown Estate ; Box 332 Horseshoe Rd. Mill Neck ; Long Island City NY 11765), Method of treatment of Alzheimer\s disease using phytic acid.
Ozaki Shoichiro (Matsuyama JPX) Watanabe Yutaka (Matsuyama JPX), Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization.
Barreto Jose C. (Pearland TX) Lichtenberger Lenard M. (Houston TX), Polyphosphorylated organic compounds: compositions useful in protecting biological tissues.
Roth Duane J. (La Jolla CA) Keipert Peter E. (San Diego CA) Faithfull Nicholas S. (Normanton by Bottesford OH GB2) Zuck Thomas F. (Cincinnati OH) Riess Jean G. (Nice FRX), Use of synthetic oxygen carriers to facilitate oxygen delivery.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.